Resonance Health Ltd. advised that it has been contracted to provide liver-fat quantification services for Invictus Ops Pty Ltd. for its clinical study ("Study") on a potential new treatment for Non-Alcoholic Steatohepatitis ("NASH"). The Company's involvement in the Study is expected to span 18 months and involve approximately 100 trial participants. Resonance Health's recently (December 2020) regulatory-cleared HepaFat- AI® medical device will be used for the first time in a clinical study environment to measure, grade, and quantify the liver fat of the trial participants at two-three timepoints over the 18-month period.

This is the first time HepaFat-AI® will be used in a third-party NASH clinical trial, which validates the efficacy of the device in a clinical trial context and establishes a precedent for other clinical trial procurement efforts in the prolific and growing fatty-liver space. The contract value is estimated to be approximately AUD 100,000 although VGI Health Technology may discontinue or extend the Study at any time in which case the Company will be paid for services performed up to the termination date.